Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06205589
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-03
First Post:
2024-01-04
Brief Title:
Therapeutic ID93 GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
Sponsor:
Organization:
Advancing Clinical Therapeutics Globally for HIVAIDS and Other Infections
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
1500
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: